The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes (ACME)
Primary Purpose
Diabetes
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
DEXA
MRI
CGM
Whole room calorimeters
Dietary counseling
Sponsored by
About this trial
This is an interventional basic science trial for Diabetes focused on measuring Obesity
Eligibility Criteria
Inclusion Criteria:
- Males and females, 19 to 30 years of age, inclusive.
Type 1 Diabetes Cohort:
- Diagnosis of type 1 diabetes for greater than 1 year at screening.
- Hemoglobin A1c 6.5-13% or
Non-Diabetic Control Cohort:
- Healthy individuals (non-diabetic) matched to T1D cohort by BMI, and gender
3. Able to provide informed consent. 4. BMI 18-39
Exclusion Criteria:
- Type 2 diabetes
- History or presence of cardiovascular disease (unstable angina, myocardial infarction or coronary revascularization within 6 months, clinically significant abnormalities on EKG, presence of cardiac pacemaker, implanted cardiac defibrillator)
- Liver disease (AST or ALT >2.5 times the upper limit of normal), history of hepatitis
- Kidney disease (creatinine >1.6 mg/dl or estimated glomerular filtration rate (GFR)<60 ml/min)
- Dyslipidemia, including triglycerides >800 mg/dl, LDL >200 mg/dl
- Anemia (hemoglobin <12 g/dl in men, <11 g/dl in women)
- Thyroid dysfunction (suppressed thyroid-stimulating hormone (TSH), elevated TSH <10 µIU/ml if symptomatic or elevated TSH >10 µIU/ml if asymptomatic)
- Uncontrolled hypertension (BP >160 mmHg systolic or > 100mmHg diastolic)
- History of cancer within the last 5 years (skin cancers, with the exception of melanoma, may be acceptable).
- Initiation or change in hormone replacement therapy within the past 3 months (including, but not limited to thyroid hormone, birth control or estrogen replacement therapy)
- History of organ transplant
- History of HIV, active Hepatitis B or C, or Tuberculosis
- Pregnancy, lactation or 6 months postpartum from screening visit
- History of major depression
- Psychiatric disease prohibiting adherence to study protocol
- History of eating disorders
- Cushing's disease or syndrome
- History of bariatric surgery
- Tobacco use within the past 3 months
- History of drug or alcohol abuse (≥3 drinks per day) within the last 5 years
- Use of oral or injectable anti-hyperglycemic agents (except insulin)
- Current use of beta-adrenergic blocking agents
- Use of antibiotics within the past 3 months
- Weight >450 lbs (This is DEXA table weight limit)
- Metal implants (pace-maker, aneurysm clips) based on Investigator's judgment at screening
- Unable to participate in MRI or magnetic resonance spectroscopy (MRS) assessment based on Investigator's judgment at screening
- Participants with strict dietary concerns (e.g. vegetarian or kosher diet, multiple food allergies, or allergies to food we will provide them during the study)
- Gastrointestinal disorders including: inflammatory bowel disease or malabsorption, swallowing disorders, suspected or known strictures, fistulas or physiological/mechanical GI obstruction, history of gastrointestinal surgery, Crohn's disease or diverticulitis.
- Presence of any condition that, in the opinion of the investigator, compromises participant safety or data integrity or the participant's ability to complete study visits
Sites / Locations
- Translational Research Institute for Metabolism and Diabetes
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Lean T1D
Obese T1D
Non-diabetic
Arm Description
Outcomes
Primary Outcome Measures
Whole Room Calorimetry
Compare 24-hour energy expenditure in patients with T1D and healthy normal volunteers that accounts for differences in hyperglycemia and body composition. 24-hour energy expenditure in kcal/24 hours after adjusting for differences in hyperglycemia (CGM) and body composition (DXA). These parameters will be measured by VO2, VC02, and urinary nitrogen.
Secondary Outcome Measures
Full Information
NCT ID
NCT03379792
First Posted
November 15, 2017
Last Updated
October 5, 2021
Sponsor
AdventHealth Translational Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT03379792
Brief Title
The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes
Acronym
ACME
Official Title
The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Unknown status
Study Start Date
March 8, 2018 (Actual)
Primary Completion Date
July 20, 2020 (Actual)
Study Completion Date
August 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AdventHealth Translational Research Institute
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to compare the metabolic phenotype of a range of body weights in individuals with and without Type 1 diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes
Keywords
Obesity
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
29 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lean T1D
Arm Type
Active Comparator
Arm Title
Obese T1D
Arm Type
Active Comparator
Arm Title
Non-diabetic
Arm Type
Active Comparator
Intervention Type
Other
Intervention Name(s)
DEXA
Intervention Description
Measurement of body composition by Dual Energy X-ray Absorptiometry (DEXA)
Intervention Type
Other
Intervention Name(s)
MRI
Intervention Description
Whole body magnetic resonance imaging (MRI)
Intervention Type
Other
Intervention Name(s)
CGM
Intervention Description
A continuous glucose monitor (CGM) will be placed on the participant and will be used as a safety measure to monitor glucose levels.
Intervention Type
Other
Intervention Name(s)
Whole room calorimeters
Intervention Description
Whole room indirect calorimetry allows for the simultaneous measure of total energy expenditure and substrate oxidation in a free living environment with multiple activities.
Intervention Type
Other
Intervention Name(s)
Dietary counseling
Intervention Description
The low carbohydrate diet counseling will be to assist young adult, overweight study participants with Type 1 diabetes in adhering to a lower calorie diet (500 calorie deficit)
Primary Outcome Measure Information:
Title
Whole Room Calorimetry
Description
Compare 24-hour energy expenditure in patients with T1D and healthy normal volunteers that accounts for differences in hyperglycemia and body composition. 24-hour energy expenditure in kcal/24 hours after adjusting for differences in hyperglycemia (CGM) and body composition (DXA). These parameters will be measured by VO2, VC02, and urinary nitrogen.
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
39 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Males and females, 19 to 30 years of age, inclusive.
Type 1 Diabetes Cohort:
Diagnosis of type 1 diabetes for greater than 1 year at screening.
Hemoglobin A1c 6.5-13% or
Non-Diabetic Control Cohort:
Healthy individuals (non-diabetic) matched to T1D cohort by BMI, and gender
3. Able to provide informed consent. 4. BMI 18-39
Exclusion Criteria:
Type 2 diabetes
History or presence of cardiovascular disease (unstable angina, myocardial infarction or coronary revascularization within 6 months, clinically significant abnormalities on EKG, presence of cardiac pacemaker, implanted cardiac defibrillator)
Liver disease (AST or ALT >2.5 times the upper limit of normal), history of hepatitis
Kidney disease (creatinine >1.6 mg/dl or estimated glomerular filtration rate (GFR)<60 ml/min)
Dyslipidemia, including triglycerides >800 mg/dl, LDL >200 mg/dl
Anemia (hemoglobin <12 g/dl in men, <11 g/dl in women)
Thyroid dysfunction (suppressed thyroid-stimulating hormone (TSH), elevated TSH <10 µIU/ml if symptomatic or elevated TSH >10 µIU/ml if asymptomatic)
Uncontrolled hypertension (BP >160 mmHg systolic or > 100mmHg diastolic)
History of cancer within the last 5 years (skin cancers, with the exception of melanoma, may be acceptable).
Initiation or change in hormone replacement therapy within the past 3 months (including, but not limited to thyroid hormone, birth control or estrogen replacement therapy)
History of organ transplant
History of HIV, active Hepatitis B or C, or Tuberculosis
Pregnancy, lactation or 6 months postpartum from screening visit
History of major depression
Psychiatric disease prohibiting adherence to study protocol
History of eating disorders
Cushing's disease or syndrome
History of bariatric surgery
Tobacco use within the past 3 months
History of drug or alcohol abuse (≥3 drinks per day) within the last 5 years
Use of oral or injectable anti-hyperglycemic agents (except insulin)
Current use of beta-adrenergic blocking agents
Use of antibiotics within the past 3 months
Weight >450 lbs (This is DEXA table weight limit)
Metal implants (pace-maker, aneurysm clips) based on Investigator's judgment at screening
Unable to participate in MRI or magnetic resonance spectroscopy (MRS) assessment based on Investigator's judgment at screening
Participants with strict dietary concerns (e.g. vegetarian or kosher diet, multiple food allergies, or allergies to food we will provide them during the study)
Gastrointestinal disorders including: inflammatory bowel disease or malabsorption, swallowing disorders, suspected or known strictures, fistulas or physiological/mechanical GI obstruction, history of gastrointestinal surgery, Crohn's disease or diverticulitis.
Presence of any condition that, in the opinion of the investigator, compromises participant safety or data integrity or the participant's ability to complete study visits
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Pratley, MD
Organizational Affiliation
Translational Research Institute for Metabolism and Diabetes
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Elizabeth Mayer-Davis, PhD
Organizational Affiliation
UNC Chapel Hill
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David M Maahs, MD, PhD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Translational Research Institute for Metabolism and Diabetes
City
Orlando
State/Province
Florida
ZIP/Postal Code
32804
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
25998289
Citation
Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015 Jun;38(6):971-8. doi: 10.2337/dc15-0078.
Results Reference
background
PubMed Identifier
25413942
Citation
Chillaron JJ, Benaiges D, Mane L, Pedro-Botet J, Flores Le-Roux JA. Obesity and type 1 diabetes mellitus management. Minerva Endocrinol. 2015 Mar;40(1):53-60. Epub 2014 Nov 21.
Results Reference
background
PubMed Identifier
20820753
Citation
Maahs DM, Ogden LG, Dabelea D, Snell-Bergeon JK, Daniels SR, Hamman RF, Rewers M. Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. Diabetologia. 2010 Dec;53(12):2518-25. doi: 10.1007/s00125-010-1886-6. Epub 2010 Sep 4.
Results Reference
background
PubMed Identifier
19636033
Citation
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group; Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009 Jul 27;169(14):1307-16. doi: 10.1001/archinternmed.2009.193.
Results Reference
background
PubMed Identifier
16776747
Citation
Jacob AN, Salinas K, Adams-Huet B, Raskin P. Potential causes of weight gain in type 1 diabetes mellitus. Diabetes Obes Metab. 2006 Jul;8(4):404-11. doi: 10.1111/j.1463-1326.2005.00515.x. Erratum In: Diabetes Obes Metab. 2006 Jul;8(4):472.
Results Reference
background
PubMed Identifier
15207844
Citation
Rigalleau V, Lasseur C, Pecheur S, Chauveau P, Combe C, Perlemoine C, Baillet L, Gin H. Resting energy expenditure in uremic, diabetic, and uremic diabetic subjects. J Diabetes Complications. 2004 Jul-Aug;18(4):237-41. doi: 10.1016/S1056-8727(03)00077-1.
Results Reference
background
PubMed Identifier
8243815
Citation
Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes. 1993 Dec;42(12):1700-7. doi: 10.2337/diab.42.12.1700.
Results Reference
background
PubMed Identifier
8586779
Citation
Greco AV, Tataranni PA, Mingrone G, De Gaetano A, Manto A, Cotroneo P, Ghirlanda G. Daily energy metabolism in patients with type 1 diabetes mellitus. J Am Coll Nutr. 1995 Jun;14(3):286-91. doi: 10.1080/07315724.1995.10718509.
Results Reference
background
PubMed Identifier
6147290
Citation
Nair KS, Halliday D, Garrow JS. Increased energy expenditure in poorly controlled Type 1 (insulin-dependent) diabetic patients. Diabetologia. 1984 Jul;27(1):13-6. doi: 10.1007/BF00253494.
Results Reference
background
PubMed Identifier
35460915
Citation
Corbin KD, Igudesman D, Addala A, Casu A, Crandell J, Kosorok MR, Maahs DM, Pokaprakarn T, Pratley RE, Souris KJ, Thomas JM, Zaharieva DP, Mayer-Davis EJ; ACT1ON Consortium. Design of the Advancing Care for Type 1 Diabetes and Obesity Network energy metabolism and sequential multiple assignment randomized trial nutrition pilot studies: An integrated approach to develop weight management solutions for individuals with type 1 diabetes. Contemp Clin Trials. 2022 Jun;117:106765. doi: 10.1016/j.cct.2022.106765. Epub 2022 Apr 20.
Results Reference
derived
Links:
URL
http://www.tri-md.org
Description
Translational Research Institute for Metabolism and Diabetes
Learn more about this trial
The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes
We'll reach out to this number within 24 hrs